MS patients are inclined to accept new therapies regardless of the potential risks, according to a survey conducted by Wayne State University in the period 2007-2009 (Caon et al AAN 2011; abstract P01.208).
A series of standardized questions were posed to 200 MS patients during a clinic visit. Patients were asked if they would consider switching to a new therapy. Treatment options were therapies with mild risk and vigilance; significant risk and vigilance; an oral therapy with mild risk and vigilance; and an oral therapy with significant risk and vigilance. ...Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2479